Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1684604

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1684604

Eosinophilic Esophagitis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

PUBLISHED:
PAGES: 130 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 6050
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Global Eosinophilic Esophagitis Market, valued at USD 366.2 million in 2024, is projected to experience an impressive CAGR of 31.4% from 2025 to 2034, driven by the rising incidence and prevalence of this chronic immune-mediated condition. This growth is fueled by a combination of increasing awareness, advancements in treatment options, and a surge in early diagnosis rates. As healthcare providers prioritize the management of rare diseases like EoE, the demand for innovative therapeutic solutions continues to rise, paving the way for significant market expansion.

Eosinophilic Esophagitis Market - IMG1

The development of targeted treatments, particularly biologics and other cutting-edge drug classes, has enhanced patient outcomes by addressing the specific inflammatory pathways associated with EoE. Furthermore, supportive healthcare policies and greater funding for research and development are bolstering innovation in this domain, making EoE a focal point of therapeutic advancements globally.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$366.2 Million
Forecast Value$5.6 Billion
CAGR31.4%

The market is categorized by drug class into biologics, corticosteroids, proton pump inhibitors, immunomodulators, and other therapies. Among these, corticosteroids emerged as the leading segment, contributing USD 137.3 million in 2024. Their proven effectiveness in alleviating inflammation and providing symptom relief, such as reducing dysphagia and chest discomfort, reinforces their position as a cornerstone of EoE management. Corticosteroids are widely adopted due to their reliability and ability to deliver rapid results, often complementing dietary modifications and other interventions.

In terms of route of administration, the market is segmented into oral, injectable, and topical options. The oral route held the largest share at 41.5% in 2024, driven by its convenience and patient-friendly nature. Oral treatments are particularly preferred for their ease of use, which promotes better adherence to long-term management plans. Recent innovations in oral therapies, such as advanced biologics and small-molecule drugs targeting inflammatory pathways, have further enhanced the efficacy of this segment. These advancements not only improve symptom control but also elevate the overall patient experience, contributing significantly to the market's growth.

The United States continues to lead the global EoE market, with a valuation of USD 151.3 million in 2024. Factors driving this dominance include rising prevalence rates, particularly among children and young adults, and the availability of advanced diagnostic and therapeutic solutions. The country's focus on managing rare and chronic diseases has resulted in substantial investments in innovative treatment options. Increased awareness among healthcare professionals and patients alike has also contributed to earlier diagnoses and improved outcomes.

Product Code: 13017

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of eosinophilic esophagitis
      • 3.2.1.2 Advancement in diagnostic techniques
      • 3.2.1.3 Development of target drug therapies
      • 3.2.1.4 Increasing healthcare investment
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Competition from generic drugs
      • 3.2.2.2 High cost of treatment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Biologics
  • 5.3 Corticosteroids
  • 5.4 Proton pump inhibitors
  • 5.5 Immunomodulators
  • 5.6 Other drug class

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Injectable
  • 6.4 Topical

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pediatric
  • 7.3 Adult
  • 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Allakos
  • 10.2 Arena Pharmaceuticals
  • 10.3 AstraZeneca
  • 10.4 Cipla
  • 10.5 Ellodi Pharmaceuticals
  • 10.6 EsoCap
  • 10.7 GlaxoSmithKline
  • 10.8 Revolo Biotherapeutics
  • 10.9 Sanofi
  • 10.10 Sun Pharmaceutical
  • 10.11 Takeda Pharmaceutical Company
  • 10.12 Teva Pharmaceutical
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!